Effects of systemic prostaglandin E1 on splanchnic and peripheral haemodynamics in control subjects and in patients with cirrhosis

被引:5
作者
Fabbri, A
Magalotti, D
Marchesini, G
Brizi, M
Bianchi, G
Zoli, M
机构
[1] Univ Bologna, Policlin S Orsola, Dipartimento Med Interna Cardioangiol Epatol, I-40138 Bologna, Italy
[2] Univ Bologna, Policlin S Orsola, Cattedra Malattie Metab, Bologna, Italy
关键词
alprostadil-alpha-ciclodextrin; systemic hemodynamics; splanchnic blood flow;
D O I
10.1016/S0090-6980(98)00020-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostaglandins of the E series showed metabolic and clinical effects in patients with liver disease; changes in splanchnic haemodynamics might be involved. Blood flow in femoral and mesenteric artery and in the portal vein was measured by echo-Doppler in 10 controls and 14 cirrhotic patients, in response to the systemic infusion of a PGE(1) analogue (30 mu g/h for 2-6 h) or saline, performed in random order. Intraparenchymal resistive and pulsatility indices in the liver, spleen and kidney were also measured. In both groups PGE(1) increased femoral artery flow by 40%, irrespective of infusion time. Heart rate increased slightly, whereas mean arterial pressure decreased. There were no changes in mesenteric artery and portal vein flow, as well as in resistance indices. Saline infusion increased femoral artery flow by 4%. PGE(1) infusion does not produces significant effects on Doppler-assessed splanchnic hemodynamics in controls and in cirrhotic patients, in spite of significant effects on peripheral circulation.
引用
收藏
页码:209 / 218
页数:10
相关论文
共 27 条
[1]   EFFECTS OF PROSTAGLANDIN INHIBITION ON SYSTEMIC AND HEPATIC HEMODYNAMICS IN PATIENTS WITH CIRRHOSIS OF THE LIVER [J].
BRUIX, J ;
BOSCH, J ;
KRAVETZ, D ;
MASTAI, R ;
RODES, J .
GASTROENTEROLOGY, 1985, 88 (02) :430-435
[2]   CIRCULATORY AND RESPIRATORY EFFECTS OF DIFFERENT DOSES OF PROSTAGLANDIN E1 IN MAN [J].
CARLSON, LA ;
EKELUND, LG ;
ORO, L .
ACTA PHYSIOLOGICA SCANDINAVICA, 1969, 75 (1-2) :161-&
[3]   DOSE PROPORTIONAL PHARMACOKINETICS OF ALPROSTADIL (PROSTAGLANDIN E(1)) IN HEALTHY-VOLUNTEERS FOLLOWING INTRAVENOUS-INFUSION [J].
CAWELLO, W ;
LEONHARDT, A ;
SCHWEER, H ;
SEYBERTH, HW ;
BONN, R ;
LOMELI, AL .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (03) :273-276
[4]  
FABBRI A, 1998, IN PRESS HEPATOLOGY
[5]   TREATMENT OF PRIMARY LIVER GRAFT NONFUNCTION WITH PROSTAGLANDIN-E1 [J].
GREIG, PD ;
WOOLF, GM ;
SINCLAIR, SB ;
ABECASSIS, M ;
STRASBERG, SM ;
TAYLOR, BR ;
BLENDIS, LM ;
SUPERINA, RA ;
GLYNN, MFX ;
LANGER, B ;
LEVY, GA .
TRANSPLANTATION, 1989, 48 (03) :447-453
[6]   EPOPROSTENOL (PROSTACYCLIN,PGI2) INCREASES APPARENT LIVER BLOOD-FLOW IN MAN [J].
HASSAN, S ;
PICKLES, H .
PROSTAGLANDINS LEUKOTRIENES AND MEDICINE, 1983, 10 (04) :449-454
[7]  
Heidrich H, 1994, INT J ANGIOLOGY, V3, P160
[8]  
HENLEY KS, 1995, HEPATOLOGY, V21, P366, DOI 10.1016/0270-9139(95)90094-2
[9]   Prostaglandins in liver transplantation: A $50,000 bonus [J].
Henley, KS ;
Smith, D .
GASTROENTEROLOGY, 1997, 112 (02) :670-671
[10]   INFLUENCE OF PRIMARY PROSTAGLANDINS, PROSTACYCLIN AND ARACHIDONIC-ACID ON MESENTERIC HEMODYNAMICS IN THE PIG [J].
HOUVENAGHEL, A ;
SCHRAUWEN, E ;
WECHSUNG, L .
PROSTAGLANDINS AND MEDICINE, 1979, 2 (02) :83-95